Published online May 21, 2020. doi: 10.3748/wjg.v26.i19.2294
Peer-review started: December 30, 2019
First decision: February 19, 2020
Revised: March 29, 2020
Accepted: May 1, 2020
Article in press: May 1, 2020
Published online: May 21, 2020
Hepatocellular adenomas (HCAs) represent rare, benign liver tumours occurring predominantly in females taking oral contraceptives. In children, HCAs comprise less than 5% of hepatic tumours and demonstrate association with various conditions. The contemporary classification of HCAs, based on their distinctive genotypes and clinical phenotypes, includes hepatocyte nuclear factor 1 homeobox alpha-inactivated HCAs, beta-catenin-mutated HCAs, inflammatory HCAs, combined beta-catenin-mutated and inflammatory HCAs, sonic hedgehog-activated HCAs, and unclassified HCAs. In children, there is a lack of literature on the characteristics and distribution of HCA subtypes. In this review, we summarized different HCA subtypes and the clinicopathologic spectrum of HCAs in the paediatric population.
Core tip: Hepatocellular adenomas (HCAs) are uncommon liver tumours with 2 major complications: bleeding and malignant transformation; these lesions are classified based on their distinctive genotypes and clinical phenotypes. HCAs in children may be identified in the setting of conditions such as glycogen storage disorder and familial adenomatous polyposis. However, the molecular subtypes do not always correlate with predisposing risk factors and syndromes. Herein, we will discuss the different subtypes of HCA and the clinicopathological characteristics in children.